Robert Clarke, PhD, executive director and professor, and Lu Jin, MS, researcher at The Hormel Institute, University of ...

Approximately two-thirds of patients with Crohn's disease who initially responded to tumor necrosis factor (TNF) inhibitors ...

Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to ...

To pass or not to pass, that is the question faced by soccer players the world over in every match. It might be unsurprising that higher skilled players exhibit better execution of actions than lower ...

Aspirin appears to boost aspects of the body's immune response against cancer cells ... or therapy with aspirin besides its ...

Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival ...

Sanofi’s $3.7 billion Principia Biopharma buyout has delivered a phase 3 victory. | Sanofi’s $3.7 billion Principia Biopharma ...

With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on BOLD stock, giving a Buy rating on April 22. Andrew Berens has ...

Boron deficiency has a devastating effect on oilseed rape and related plants. However, little is known about the underlying ...

The FDA on Tuesday approved Day One Biopharmaceuticals’ type II RAF inhibitor Ojemda, which is designed to penetrate the ...

Sanofi’s rilzabrutinib met the primary endpoint in the Phase III persistent or chronic immune thrombocytopenia trial.